
Eric H Bernicker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2791808/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Updated Molecular Testing Guideline for theÂSelection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2018, 13, 323-358.	0.5	408
2	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Journal of Molecular Diagnostics, 2018, 20, 129-159.	1.2	241
3	Combined Blockade of Activating <i>ERBB2</i> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. Clinical Cancer Research, 2019, 25, 277-289.	3.2	74
4	Practice Patterns and Outcomes in Elderly Stage I Non–Small-cell Lung Cancer: A 2004 to 2012 SEER Analysis. Clinical Lung Cancer, 2018, 19, e269-e276.	1.1	53
5	A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Science Translational Medicine, 2021, 13, eabj5070.	5.8	48
6	Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma. Clinical Lung Cancer, 2020, 21, 437-442.	1.1	26
7	Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Archives of Pathology and Laboratory Medicine, 2017, 141, 1529-1532.	1.2	24
8	Update on emerging biomarkers in lung cancer. Journal of Thoracic Disease, 2019, 11, S81-S88.	0.6	23
9	Disparities in the Treatment and Outcome of Stage I Non–Small-Cell Lung Cancer in the 21st Century. Clinical Lung Cancer, 2019, 20, 194-200.	1.1	22
10	Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 1541-1545.	1.0	20
11	Cancer cachexia: a multifactoral disease that needs a multimodal approach. Current Opinion in Gastroenterology, 2020, 36, 141-146.	1.0	18
12	Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer. Archives of Pathology and Laboratory Medicine, 2015, 139, 1477-1478.	1.2	17
13	Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center. Journal of Oncology Pharmacy Practice, 2019, 25, 1564-1569.	0.5	17
14	Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung. Journal of Oncology Practice, 2017, 13, 221-227.	2.5	15
15	Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective. Archives of Pathology and Laboratory Medicine, 2016, 140, 245-248.	1.2	11
16	Management of pathologic node-positive disease following initial surgery for clinical T1-2 N0 esophageal cancer: patterns of care and outcomes from the national cancer data base. Acta Oncológica, 2018, 57, 782-789.	0.8	11
17	Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib. Translational Lung Cancer Research, 2021, 10, 1525-1535.	1.3	11
18	The Gut Microbiome Influences Responses to Programmed Death 1 Therapy in Chinese Lung Cancer Patients — the Benefits of Diversity. Journal of Thoracic Oncology, 2019, 14, 1319-1322.	0.5	10

ERIC H BERNICKER

#	Article	IF	CITATIONS
19	Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non‧mall Cell Lung Cancer in U.S. Community Medical Centers. Oncologist, 2021, 26, e1050-e1057.	1.9	10
20	Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database. Journal of Contemporary Brachytherapy, 2020, 12, 303-310.	0.4	7
21	Osimertinib induced cardio-toxicity: A retrospective review of FDA adverse events reporting system (FAERS) Journal of Clinical Oncology, 2019, 37, 9044-9044.	0.8	7
22	A New Immunotherapy Drug Creates a Watershed for the Surgical Pathologist's Role in Patient Care. Archives of Pathology and Laboratory Medicine, 2015, 139, 1329-1330.	1.2	6
23	Biomarker Testing in Non–Small Cell Lung Cancer: A Clinician's Perspective. Archives of Pathology and Laboratory Medicine, 2015, 139, 448-450.	1.2	6
24	A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP) Journal of Clinical Oncology, 2021, 39, 1079-1079.	0.8	6
25	Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Cancer. American Journal of Clinical Pathology, 2018, 150, S143-S143.	0.4	5
26	Panuveitis in patient on ipilimumab/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant. Journal of Oncology Pharmacy Practice, 2020, 27, 107815522096979.	0.5	5
27	Chemotherapy in non-small cell lung cancer: opportunities for advancement. Chinese Journal of Cancer, 2016, 35, 56.	4.9	4
28	What the Oncologist Needs From the Pathologist for Tyrosine Kinase Inhibitor Therapies. Archives of Pathology and Laboratory Medicine, 2019, 143, 1089-1092.	1.2	4
29	Socioeconomic Factors Associated with Lack of Treatment in Early Stage Non-Small Cell Lung Cancer. Cancer Investigation, 2019, 37, 506-511.	0.6	4
30	Stereotactic body radiation therapy and in situ oncolytic virus therapy followed by immunotherapy in metastatic non-small cell lung cancer Journal of Clinical Oncology, 2021, 39, 9115-9115.	0.8	4
31	IMpower150: Exploratory efficacy analysis in patients (pts) with bulky disease Journal of Clinical Oncology, 2020, 38, e21637-e21637.	0.8	4
32	Time Interval to Initiation of Whole-Brain Radiation Therapy in Patients With Small Cell Lung Cancer With Brain Metastasis. Advances in Radiation Oncology, 2021, 6, 100783.	0.6	3
33	DMSA-SPECT: A Novel Approach to Nephron Sparing SBRT for Renal Cell Carcinoma. Advances in Radiation Oncology, 2021, 6, 100719.	0.6	3
34	Understanding Factors Associated With Anaplastic Lymphoma Kinase Testing Delays in Patients With Non–Small Cell Lung Cancer in a Large Real-World Oncology Database. Archives of Pathology and Laboratory Medicine, 2022, 146, 975-983.	1.2	3
35	Three-year outcomes of uveal melanoma treated with intra-operative ultrasound-guided iodine-125 brachytherapy using custom-built eye plaques. Journal of Contemporary Brachytherapy, 2022, 14, 130-139.	0.4	2
36	Molecular Signatures of <i>KRAS</i> -Mutated Lung Adenocarcinoma: Analysis of Concomitant <i>EGFR</i> , <i>ALK</i> , <i>STK11</i> , and PD-L1 Status. BMC Clinical Pathology, 2022, 15, 2632010X2211020.	0.7	2

ERIC H BERNICKER

#	Article	IF	CITATIONS
37	A Matter of Comprehensive Informed Consent. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 851-855.	0.6	1
38	Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience. Journal of Thoracic Disease, 2021, 13, 4785-4796.	0.6	1
39	Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2017, 35, 9025-9025.	0.8	1
40	Prevalence of ALK mutations in advanced NSCLC patients in the United States: Analysis with a real world oncology database Journal of Clinical Oncology, 2020, 38, e21586-e21586.	0.8	1
41	Anaplastic lymphoma kinase rearrangement prevalence in patients with advanced non-small cell lung cancer in the United States - retrospective real world data. Oncotarget, 2021, 12, 2308-2315.	0.8	1
42	Contemporary trends in management of uveal melanoma. Journal of Contemporary Brachytherapy, 2022, 14, 123-129.	0.4	1
43	NCMP-08. MANAGEMENT OF RADIONECROSIS AFTER STEREOTACTIC RADIATION FOR BRAIN METASTASES IN THE SETTING OF IMMUNE CHECKPOINT INHIBITORS. Neuro-Oncology, 2018, 20, vi195-vi195.	0.6	Ο
44	What the Oncologist Needs From the Pathologist for Immune Therapies. Archives of Pathology and Laboratory Medicine, 2019, 143, 1513-1516.	1.2	0
45	31. RADIATION NECROSIS IN STEREOTACTIC RADIOSURGERY AND CHECKPOINTS INHIBITORS FOR BRAIN METASTASES FROM LUNG ADENOCARCINOMA. Neuro-Oncology Advances, 2020, 2, ii5-ii5.	0.4	Ο
46	Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors. JTO Clinical and Research Reports, 2020, 1, 100017.	0.6	0
47	The utility of PET-CT after preoperative chemoradiation in predicting treatment outcomes in locally advanced esophageal cancer Journal of Clinical Oncology, 2018, 36, 182-182.	0.8	Ο
48	Community-based Disparities in the Treatment and Outcomes of Early-stage Non-small-cell Carcinoma . Cureus, 2019, 11, e5889.	0.2	0
49	Real-world testing compliance to NCCN guideline and factors of underutilization in U.S. community clinics Journal of Clinical Oncology, 2020, 38, e21592-e21592.	0.8	0